Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH)

Author Information

Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi.

Corresponding author:

Dr. Oliech J.S., P.O Box 30197-00100, Nairobi. E-mail: jsoliech@yahoo.com

Abstract

Background: The incidence of benign prostatic hyperplasia peaks 80% in old age. Bothersome symptoms and progression to acute urinary retention and need for surgery are important concerns. Apha blockers and 5 alpha reductase inhibitors address these to variable extents. This article reviews the current place of medical therapy in the treatment of BPH, with a focus on combination therapy.

Data Source: A medline literature search was performed to identify original studies including global multi-center trials and reviews on the subject.

Conclusion: BPH symptom reduction and shrinkage of prostate size by the use of a combination of alpha adrenergic uroselective blocker (Tamsulosin) and 5 alpha iso-enzyme inhibitor (Dutasteride) is a first option of therapy in the management of BPH especially in those cases that are surgical risks with the category of mild to moderate prostate symptom scores.

ssk_logo.png

The Annals of African Surgery is the official publication of the Surgical Society of Kenya.

 

All content copyright © 2020 Annals of African Surgery.

ISSN (print): 1999-9674; ISSN (online): 2523-0816

Main Office Location: Menelik Medical Centre, Menelik Road, off Ngong Road, Nairobi. First floor.

Telephone: +254715260499

Email: info@annalsofafricansurgery.com.

 

The content on this site is intended for health professionals. Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.

70.png
69.jpg
hinari_header_en.png
  • Twitter
  • Facebook Social Icon
  • LinkedIn